3 / 15
Page 19
J u l y 2 3 - 2 4 , 2 0 1 8 | R o m e , I t a l y
Note:
allied
academies
Joint Event on
Cardiology Congress 2018 & Microbe Infection 2018
Biomedical Research
|
ISSN: 0976-1683
|
Volume 29
2
nd
World Congress on
CARDIOLOGY
MICROBIOLOGY AND MICROBIAL INFECTION
&
39
th
Annual Congress on
Markus Bredemeier, Biomed Res 2018, Volume 29 | DOI: 10.4066/biomedicalresearch-C1-002
EFFECT OF XANTHINE OXIDASE INHIBITORS
ON CARDIOVASCULAR OUTCOMES: TRYING
TO MAKE SENSE OF THE CONTRADICTORY
EVIDENCE
Markus Bredemeier
Hospital Nossa Senhora da Conceição, Brazil
X
anthine oxidase inhibitors (XOI), classified as purine-like (allopurinol and
oxypurinol) and non-purine (febuxostat and topiroxostat) XOI, present
antioxidant properties by reducing the production of reactive oxygen species
derived from purine metabolism. Oxidative stress is an important factor
related to endothelial dysfunction and ischemia-reperfusion injury and may
be implicated in the pathogenesis of heart failure, hypertension and ischemic
heart disease. However, there is contradictory evidence regarding the possible
cardiovascular (CV) protective effect exerted by XOI, especially regarding the
results of randomized controlled trials. In the present lecture, we discuss
in deep the reasons for the disparity in results of different studies from a
pharmacodynamic and clinico-epidemiologic point of view, considering the
emergence of recent evidence in this field.
Markus Bredemeier is graduated fromMedical School
at Federal University of Rio Grande do Sul (1994) and
obtained master’s (2003) and PhD (2006) in Medicine:
Medical Sciences. Currently, he is practicing at Grupo
Hospitalar Conceição (GHC). He worked as Professor
of Clinical Pharmacology at the Faculty of Dentistry,
Lutheran University of Brazil, from 1997 to 2005. He
has 55 scientific articles published in medical jour-
nals, of which 42 are indexed in PubMed. He founded
and supervises the residency program in Rheuma-
tology of the GHC. In October 2013, he received the
award Luiz Felipe Cunha Mattos (first place) for the
work low- versus high-dose rituximab for rheumatoid
arthritis: a systematic review and meta-analysis. The
updated version of this study was presented orally at
the EULAR 2015 Congress. In 2017, presented orally
the study effect of xanthine oxidase inhibitors on the
incidence of cardiovascular events: a systematic re-
view and meta-analysis of randomized controlled tri-
als at the EULAR Congress Madrid.
markbred@terra.com.brBIOGRAPHY